BioSpace News Archive

The Pancreatic Cancer Early Detection (PRECEDE) Consortium, a beacon of hope in the global fight against pancreatic cancer, hosted its fifth annual meeting at the Cornell Tech Verizon Center on Roosevelt Island.

Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Dec. 9-12 in San Diego.

Promore Pharma AB announced on 29 November 2023 the reverse acquisition of PMD Device Solutions AB and PMD’s intended private placement of shares in PMD prior to the Reverse Acquisition.

The board of directors of Eli Lilly and Company has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2024 of $1.30 per share on outstanding common stock.

Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.

The global cancer monoclonal antibodies market size is estimated to reach around USD 410.95 billion by 2032, increasing from USD 89.06 billion in 2023.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.

bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird bio” or “bluebird”) today announced the U.S. Food and Drug Administration (FDA) has approved LYFGENIA™ (pronounced as ‘lif-JEN-ee-uh’) (lovotibeglogene autotemcel), also known as lovo-cel, for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).

LSL Pharma Group Inc. is pleased to announce that the Company has closed the second tranche of its brokered private placement through the issuance of 99,500 unsecured convertible debentures at a price of $10 per Debenture for gross proceeds of $995,000.

Astellas Pharma US, Inc. (President: Mark Reisenauer, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved CRESEMBA® (isavuconazonium sulfate), an azole antifungal drug, for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients.